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Table 1
Risk factors of Hemorrhagic cystitis
Risk factors
Hazard ration
(95% CI) P-value
Age (years) 1.07 (1.02 e 1.12) 0.004
Male Male vs female 2.78 (0.63 e 12.5) 0.177
Keratinocyte
growth factor
Yes vs No 0.23 (0.03 e 1.92) 0.175
Mismatched donor Mismatched donor
vs matched donor
1.05 (0.30 e 3.66) 0.943
T-cell depleted TCD vs CONV 0.57 (0.16 e 1.99) 0.379
Cord blood
allografts
Cord blood vs
PBSC
2.23 (0.56 e 8.91) 0.256
Total body
irradiation
Yes vs No 0.61 (0.16 e 2.30) 0.46
aGVHD 2-3 aGVHD 2-3 vs
aGVHD 0-1
3.51 (0.64 e 19.33) 0.149
3-log BKV rise in
the urine
Yes vs No 1.98 (0.48 e 8.09) 0.344
Ciproﬂoxacin use* Yes vs No 0.17 (0.02 e 1.32) 0.091
Pre-HSCT urine BKV
‡ 107 copies/mL
107 copies/mLvs
<107 copies/mL
8.60 (2.35 e 31.40) 0.001
Post-HSCT urine BKV
‡ 107 copies/mL
107 copies/mLvs
<107 copies/mL
8.08 (1.85 e 35.26) 0.005
CONV indicates: Umbilical cord stem cell allografts, unmodiﬁed bone
marrow, and peripheral blood
* Ciproﬂoxacin use: from day -14 HSCT until day 14 post-HSCT
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Background: Hemorrhagic cystitis (HC) is a frequent
complication after HSCT and can signiﬁcantly affect the
patient's quality of life. BK virus (BKV), chemotherapy, irra-
diation, and graft versus host disease (GVHD) have been
associated with the pathogenesis of HC. To investigate the
relationship of HC and BKV, we prospectively evaluated
patient's BKV pre-HSCT serology and BKV in the urine, and
the association between BKV viruria and HC.
Methods: From April 2010 through October 2011, we
prospectively followed 98 adult HSCT patients. The patients
were monitored for BKV in the urine by quantitive poly-
merase chain reaction (Q-PCR) every 2 weeks from start of
conditioning until 15 weeks post-HSCT. Pre-HSCT BKV IgG
titers were measured by ELISA. All tests were performed by
Viracor-IBT Laboratories. BKV viruria was deﬁned as: 1
Q-PCR assay of >500 copies/mL; PEAK: 3-log increase in
BKV Q-PCR from pre-HSCT Q-PCR. A chart review was per-
formed to determine the development of HC. HC was graded
according to Bedi et al and was considered signiﬁcant if 
grade 2. Ciproﬂoxacin use was included from day -14
through day +14 post-transplant. Competing regression was
performed using clinical characteristics and urine BKV PCRs
to identify risk factors for development of HC.
Results: The median age of the patients was 52 years (range
20-73), 60% were male, 49% of patients underwent myeloa-
blative conditioning, 50% received T-cell depleted, and 21%
cord blood grafts. Acute grade 2-3 GVHD was diagnosed in
32% of patients and 31% had received Keratinocyte growth
factor (KGF) pretransplant. All patients (100%) were BKV IgG
positive pretransplant. By day 0, the cumulative incidence
(CI) of BKV viruria was 22%. By day+30, the CI was 50% and it
remained stable thereafter for the duration of the study. The
CI rates for BKV were similar among different stem cell
sources. Ten patients (10%) patients developed HC at
a median 40 days post transplant (range 0-146) and 7/10
(70%) patients with HC had BKV (2 with concomitant
adenovirus). Risk factors for HC were older age (P ¼ .004),
and BK viruria 107 copies/mL either pre- (P ¼ .001) or post-
HSCT (P ¼ .005). One of 30 patients (3%) who received KGF
developed HC and 9 of 68 patients (13%) who did not receive
KGF developed HC (P ¼ .175). One of 35 patients (3%) who
received ciproﬂoxacin developed HC and 9 of 63 patients
(14%) who did not receive ciproﬂoxacin developed HC
(P ¼ .091). During the study period, 36 patients died and 8
patients had autopsies performed. One of the 8 patients was
found to have BKV nephropathy at autopsy.
Conclusions: 1) In this study, the incidence of BK viruria was
not signiﬁcantly different among various stem cell sources.
2) High level BK viruria (107 copies/mL) and older age were
signiﬁcant predictors of HC. 3) While BK viruria was frequent(50%) during the study period, the rate of HC was low (10%)
suggesting additional co-factors in the pathogenesis of HC.376
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The Impact of Comorbidity and Performance Status in
Patients Undergoing Myeloablative Transplant Most diseases
treated by hematopoietic stem cell transplant (HSCT) occur
in individuals greater than 45 years of age. With the aging
population and the advent of new transplant regimens, the
incidence of comorbidities in the transplant patient pop-
ulation is increasing. Intensive chemotherapy causes
increased non-relapse mortality in this population. The
primary objective of this study is to determine if an associ-
ation exists between non-relapse mortality and calculated
comorbidity index (CMI) and Karnofsky performance (KPS)
scores in patients undergoing myeloablative preparative
regimens for HSCT. Secondary objectives were to assess the
impact of insurance on overall survival, speciﬁcally with high
CMI cases. We conducted a cross-sectional chart review of
HSCT patients at the Oklahoma tertiary referral hospital.
Eligible patients included adults ages 18-99 who received
amyeloablative allogeneic HSCT between 2007 and 2011. The
age range in our population ranged from 18-59. Data was
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tiﬁed manner. This study was approved by the institutional
review board of the University of Oklahoma Health Sciences
Center. Patient comorbidity index scores were calculated
within 30 days of transplant using the QxMD Hematopoietic
Cell Transplantation-Speciﬁc Index (HCT-CI) calculator. Kar-
nofsky Performance Status was determined by a physician
during pre-transplant assessment. Additional pre-transplant
data collected included: gender, age at transplant, date of
transplant, donor type, donor source, preparative method,
speciﬁc preparative regimen, disease status at the time of
transplant, disease type, and insurance status. Post-trans-
plant data collected included: survival at 100 days, 1 year,
and 2 years post-transplant, cause of death, presence of
graft-versus-host disease (GVHD), type of GVHD, organ
affected by GVHD, and documented infections. Our results
indicated that higher CMI scores were signiﬁcantly associ-
ated with increased non-relapse mortality in patients
undergoing myeloablative transplant preparative regimens
(P < .001). Lower KPS scores were also signiﬁcantly associ-
ated with poor survival ( P < .001). Insurance was not
signiﬁcantly associated with non-relapse mortality (P > .05).
Finally, 39% of all patient deaths were attributed to disease,
20% of patient deaths were attributed to non-relapse
mortality, while 41% of patients survived.377
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Introduction: Reduced intensity conditioning (RIC) with
alemtuzumab, ﬂudarabine, and melphalan improves the
hematopoietic cell transplant (HCT) outcomes of patients
with hemophagocytic lymphohistiocytosis (HLH). Proximal
dosing of alemtuzumab is associated with a high incidence of
mixed chimerism (MC) whereas distal dosing is associated
with less MC but higher incidences of acute GVHD following
initial graft infusion. We hypothesized that an intermediate
alemtuzumab schedule would optimize the incidences of MC
and acute GVHD.
Methods: Twenty-ﬁve consecutive transplants were per-
formed in patients with HLH or XLP using a RIC regimenwith
a novel intermediate alemtuzumab schedule of 1mg/kg
beginning on day -14. The cumulative incidences of MC and
acute GVHD were compared to 2 retrospective cohorts of
patients with HLH and XLP treated with distal (n¼15) or
proximal (n¼33) alemtuzumab schedules. All patients
received ﬂudarabine 150mg/M2 (1mg/kg if <10kg) divided
over days -8 to -4, and melphalan 140mg/M2 (4.7mg/kg if
<10kg) on day -3. Melphalan was reduced by 50% in one
infant due to concern for toxicity. GVHD prophylaxis con-
sisted of methylprednisolone and cyclosporine or tacrolimus
in all but 2 patients who received methylprednisolone and
MMF. Three patients additionally received methotrexate.
Results: The cumulative incidence of MC was less in the
intermediate alemtuzumab cohort at 34%, versus 72% in theproximal and 40% in the distal cohorts (P ¼ .008). The
cumulative incidence of acute GVHD related to initial graft
infusion (before MC) was 4% in the intermediate cohort and
0% in the proximal cohort (P ¼ .26), versus 13% in the distal
cohort (P ¼ .04, proximal versus distal). There was a trend
toward less overall acute GVHD (following graft infusion or
following intervention for MC) in the intermediate cohort
at 12%, versus 16% and 27% in the proximal and distal cohorts
(P ¼ .55).
Conclusion: This novel 14 day RIC regimen optimizes the
incidences of MC and acute GVHD.378
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Introduction: The allogeneic hematopoietic cell trans-
plantation (alloHCT) remains the only treatment modality
with known curative potential in MDS, AML and CMML. The
5-azacitidine is the ﬁrst line treatment in high-risk MDS that
are not suitable for intensive therapy. On the other hand,
there is not enough evidence for deciding which is the best
option, either 5-azacitidine or induction chemotherapy,
before alloHCT. In a similar way, the 5-azacitidine exposure
in post-alloHCT relapsemay be an attractive alternative, even
though there are not deﬁnite results yet.
Objective: Evaluate the capacity of 5-azacitidine in reducing
or stabilizing the disease before alloHCT, regarding associ-
ated toxicity, and its role in post-alloHCT relapses.
Patients And Methods: We retrospectively reviewed 36
patients who underwent alloHCT for high-risk MDS, AML
and CMML between October 2006 and September 2012 in
our center and who received 5-azacitidine before and/or
after alloHCT.
Results: 30 patients received 5-azacitidine pre-alloHCT, 22
were MDS (73%), 6 AML (22%) and 2 CMML (7%), with high-
risk cytogenetic (according to IPSS-R) in one third of them.
The median of cycles was 5 (1-12), using the conventional
dose and schedule, and presenting usual toxicity in only 38%
of cases. Two thirds of evaluable patients achieved complete
remission (CR) or partial response (PR) and 26% progressed.
83% of patients underwent alloHCT in some type of response
and 17% in progression. The alloHCT characteristics were:
median of age of 56 (35-67), peripheral blood as source of
stem cells in 93%, related donor in 62%, and reduced-inten-
sity conditioning in most cases (83%). At day +100, 82% of
patients achieved CR and 18% had progressed. The global
post-alloHCT relapse rate was 33%. The 2-years overall
survival (OS) and event-free survival (EFS) were 66% and 50%,
respectively. At 1 year, the relapse-free survival (RFS) was
65%, without having reached the median follow-up. We did
not observe any signiﬁcant statistical differences in OS after
taking into account the following factors: sex, diagnosis,
previous lines of treatment, response to 5-azacitidine,
response at alloHCT and type of donor. However, cytogenetic
risk did signiﬁcantly inﬂuence survival in terms of OS, EFS
and RFS, the same as source of stem cells, type of condi-
tioning regimen and response at day +100 in OS. 16 patients
received 5-azacitidine after post-alloHCT relapse with
a median of cycle of 3.5 (1-19), reduced dose in some cases
and limited toxicity (42%). The median of days after alloHCT
to the beginning of treatment was 152 (32-529). Two thirds
